# A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

> **NCT07049055** · PHASE1,PHASE2 · RECRUITING · sponsor: **Engeneic Pty Limited** · enrollment: 144 (estimated)

## Conditions studied

- Pancreatic Cancer, Metastatic
- PDAC - Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** E-EDV-D682
- **DRUG:** EDV-GC
- **DRUG:** Gemcitabine
- **DRUG:** Nab paclitaxel.

## Key facts

- **NCT ID:** NCT07049055
- **Lead sponsor:** Engeneic Pty Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-12
- **Primary completion:** 2028-09
- **Final completion:** 2028-09
- **Target enrollment:** 144 (ESTIMATED)
- **Last updated:** 2026-02-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07049055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07049055, "A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07049055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*